Companies
Roche
World's largest biotech — pioneered monoclonal antibodies with Herceptin/Rituxan; Genentech subsidiary leads oncology and personalized medicine biologics R&D.
- Country
- Switzerland
- Revenue
- CHF 58.7B
- Employees
- ~100,000 emp
GMP EU
FDA GMP
ICH Q7
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| analytics-pat | ✓ | ✓ | — | ✓ |
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | CHF 62.598 billion (2025-12-31) | contractpharma.com |
| Funding | USD 50 billion investment in US pharmaceuticals and diagnostics over five years (2025-04-22) | assets.roche.com · contractpharma.com |
| Production site | 13 manufacturing sites in the United States (2025-04-22) | assets.roche.com · roche.com |
| Production site | 65,000 square meter manufacturing facility in Holly Springs, North Carolina (2025-08-25) | contractpharma.com · roche.com |
| Certification | EU-GMP, US-FDA, UK-MHRA, and Japan-PMDA certified facilities (2026-06-01) | chemxpert.com |
| Regulatory approval | FDA and EU approvals for various biologics including Gazyva/Gazyvaro, Ocrevus Zunovo, and Tecentriq Hybreza (2025-12-31) | assets.roche.com · pharmadossier.com · roche.com |
Independent sources: chemxpert.com · contractpharma.com · pharmadossier.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated nucleic acid extraction | analytics-pat | Low | → |
| Biologics | therapeutics-platforms | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| Diagnostics & biosensors | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.